Develops immune modulation drugs for autoimmune diseases.
Mar 2026Revenue $14.3K/yrExpenses $18.3M/yr
No trend
Figures by year
When will Aditxt be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Mar 2026, revenue was $14.3K and expenses $18.3M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $3.19K | $19.6M | −$19.6M |
| Dec 2024 | $134K | $28.0M | −$27.9M |
| Dec 2023 | $645K | $26.7M | −$26.1M |
| Dec 2022 | $934K | $26.4M | −$25.5M |
| Dec 2021 | $105K | $42.0M | −$41.9M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.